Healthcare Delivery and Huntington's Disease During the Time of COVID-19.


Journal

Journal of Huntington's disease
ISSN: 1879-6400
Titre abrégé: J Huntingtons Dis
Pays: Netherlands
ID NLM: 101589965

Informations de publication

Date de publication:
2021
Historique:
pubmed: 27 4 2021
medline: 10 7 2021
entrez: 26 4 2021
Statut: ppublish

Résumé

Safer-at-home orders during the COVID-19 pandemic altered the structure of clinical care for Huntington's disease (HD) patients. This shift provided an opportunity to identify limitations in the current healthcare infrastructure and how these may impact the health and well-being of persons with HD. The study objectives were to assess the feasibility of remote healthcare delivery in HD patients, to identify socioeconomic factors which may explain differences in feasibility and to evaluate the impact of safer-at-home orders on HD patient stress levels. This observational study of a clinical HD population during the 'safer-at-home' orders asked patients or caregivers about their current access to healthcare resources and patient stress levels. A chart review allowed for an assessment of socioeconomic status and characterization of HD severity. Two-hundred and twelve HD patients were contacted with 156 completing the survey. During safer-at-home orders, the majority of HD patients were able to obtain medications and see a physician; however, 25% of patients would not commit to regular telehealth visits, and less than 50% utilized an online healthcare platform. We found that 37% of participants were divorced/single, 39% had less than a high school diploma, and nearly 20% were uninsured or on low-income health insurance. Patient stress levels correlated with disease burden. A significant portion of HD participants were not willing to participate in telehealth services. Potential explanations for these limitations may include socioeconomic barriers and caregiving structure. These observations illustrate areas for clinical care improvement to address healthcare disparities in the HD community.

Sections du résumé

BACKGROUND
Safer-at-home orders during the COVID-19 pandemic altered the structure of clinical care for Huntington's disease (HD) patients. This shift provided an opportunity to identify limitations in the current healthcare infrastructure and how these may impact the health and well-being of persons with HD.
OBJECTIVE
The study objectives were to assess the feasibility of remote healthcare delivery in HD patients, to identify socioeconomic factors which may explain differences in feasibility and to evaluate the impact of safer-at-home orders on HD patient stress levels.
METHODS
This observational study of a clinical HD population during the 'safer-at-home' orders asked patients or caregivers about their current access to healthcare resources and patient stress levels. A chart review allowed for an assessment of socioeconomic status and characterization of HD severity.
RESULTS
Two-hundred and twelve HD patients were contacted with 156 completing the survey. During safer-at-home orders, the majority of HD patients were able to obtain medications and see a physician; however, 25% of patients would not commit to regular telehealth visits, and less than 50% utilized an online healthcare platform. We found that 37% of participants were divorced/single, 39% had less than a high school diploma, and nearly 20% were uninsured or on low-income health insurance. Patient stress levels correlated with disease burden.
CONCLUSION
A significant portion of HD participants were not willing to participate in telehealth services. Potential explanations for these limitations may include socioeconomic barriers and caregiving structure. These observations illustrate areas for clinical care improvement to address healthcare disparities in the HD community.

Identifiants

pubmed: 33896846
pii: JHD200460
doi: 10.3233/JHD-200460
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

313-322

Auteurs

Anna C Pfalzer (AC)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Lisa M Hale (LM)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Elizabeth Huitz (E)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Danielle A Buchanan (DA)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Brittany K Brown (BK)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Sarah Moroz (S)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Renee M Rouleau (RM)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Kaitlyn R Hay (KR)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Jennifer Hoadley (J)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Amy Laird (A)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Abagail E Ciriegio (AE)

Department of Psychology and Human Development, Vanderbilt University Medical Center, Nashville, TN, USA.

Kelly H Watson (KH)

Department of Psychology and Human Development, Vanderbilt University Medical Center, Nashville, TN, USA.

Maile T Jones (MT)

Department of Psychology and Human Development, Vanderbilt University Medical Center, Nashville, TN, USA.

Ya-Chen Lin (YC)

Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA.

Hakmook Kang (H)

Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA.

Heather Riordan (H)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

David A Isaacs (DA)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Katherine E McDonell (KE)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Bruce E Compas (BE)

Department of Psychology and Human Development, Vanderbilt University Medical Center, Nashville, TN, USA.

Daniel O Claassen (DO)

Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH